JAK Inhibitor Crystalline Form 1 Stabilization

The patent identifies and characterizes different crystalline forms (polymorphs) of the JAK inhibitor compound, each with distinct physical parameters such as melting point, solubility, and hygroscopicity. By selecting specific crystalline forms with optimized parameters, the patent achieves both formulation versatility and enhanced stability, resolving the contradiction between adaptability and reliability.

The patent characterizes specific local properties of different crystalline forms, including their hygroscopicity, melting behavior, and molecular packing arrangements. By selecting crystalline forms with favorable local quality characteristics (lower hygroscopicity, appropriate melting points), the patent achieves both high therapeutic efficacy and resistance to hydrate conversion, resolving the contradiction between reliability and compositional stability.

The patent employs preliminary crystallization steps and selective solvent systems that promote the formation of the desired stable crystalline form while preventing hydrate formation during the initial synthesis and isolation stages. By performing purification actions in advance and selecting appropriate crystallization conditions, the patent reduces the need for complex subsequent purification steps, resolving the contradiction between compositional stability and process complexity.